George C. Prendergast

Lankenau Institute for Medical Research 
Cancer Research
"George Prendergast"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Manley K, Bravo-Nuevo A, Minton AR, et al. (2019) Preclinical study of the long-range safety and anti-inflammatory effects of high-dose oral meglumine. Journal of Cellular Biochemistry
Almonte-Baldonado R, Bravo-Nuevo A, Gerald D, et al. (2018) RhoB antibody alters retinal vascularization in models of murine retinopathy. Journal of Cellular Biochemistry
Winters M, DuHadaway JB, Pham KN, et al. (2018) Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase. European Journal of Medicinal Chemistry. 162: 455-464
Thomas S, Hoxha K, Alexander W, et al. (2018) Intestinal barrier tightening by a cell-penetrating antibody to Bin1, a candidate target for immunotherapy of ulcerative colitis. Journal of Cellular Biochemistry
Nevler A, Muller AJ, Sutanto-Ward E, et al. (2018) Host gene status influences tumor progression and radiotherapy response in -driven sporadic pancreatic cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Fox E, Oliver T, Rowe M, et al. (2018) Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. Frontiers in Oncology. 8: 370
Muller AJ, Manfredi MG, Zakharia Y, et al. (2018) Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Seminars in Immunopathology
Nevler A, Muller AJ, Cozzitorto JA, et al. (2018) A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss of Function Polymorphisms and Indoleamine-2,3-Dioxygenase-2. Journal of the American College of Surgeons
Prendergast GC, Malachowski WJ, Mondal A, et al. (2018) Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer. International Review of Cell and Molecular Biology. 336: 175-203
Prendergast GC, Mondal A, Dey S, et al. (2018) Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'. Trends in Cancer. 4: 38-58
See more...